Nanopharmaceutics is focused on the development of innovative therapeutic products aimed at treating various medical conditions, including cancer, central nervous system (CNS) disorders, and infectious diseases. The company has established a robust clinical pipeline that features a range of oral, topical, and injectable small molecule drug candidates. Among its proprietary and partnered programs are notable products such as Triapine®, which targets cancer, and NanoBUP™, which is designed for CNS disorders. Additionally, the pipeline includes Ramoplanin™ and NanoDOX™, both of which are aimed at combating infectious diseases, showcasing the company's commitment to addressing significant health challenges.

The company's approach emphasizes the development of targeted therapies, with a total of nine clinical-stage programs currently in progress. This includes both proprietary and partnered initiatives, indicating a collaborative effort in advancing these therapeutic candidates. Furthermore, Nanopharmaceutics is also working on a substantial portfolio of preclinical development candidates, which suggests a strong pipeline for future innovations. Overall, the company's mission is to leverage its scientific expertise to create effective treatments that can significantly improve patient outcomes in critical areas of healthcare.

United States

Nanopharmaceutics, Inc. is a clinical-stage specialty pharmaceutical company developing oral, topical, and injectable products for cancer, central nervous system (CNS) disorders, and infectious diseases. Leveraging its expertise in nanoparticle and fine-particle formulations, which can specifically be used to improve hard-to-deliver BCS category II and IV drugs, Nanopharmaceutics is focused on formulation development aimed at improving drug absorption and stability.

Nanopharmaceutics

Company Details